<SEC-DOCUMENT>0001140361-24-028247.txt : 20240531
<SEC-HEADER>0001140361-24-028247.hdr.sgml : 20240531
<ACCEPTANCE-DATETIME>20240531071531
ACCESSION NUMBER:		0001140361-24-028247
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20240531
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240531
DATE AS OF CHANGE:		20240531

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IONIS PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000874015
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				330336973
		STATE OF INCORPORATION:			CA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19125
		FILM NUMBER:		241007670

	BUSINESS ADDRESS:	
		STREET 1:		2855 GAZELLE COURT
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92010
		BUSINESS PHONE:		7609319200

	MAIL ADDRESS:	
		STREET 1:		2855 GAZELLE COURT
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ISIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ef20030319_8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:cef="http://xbrl.sec.gov/cef/2023" xmlns:ions="http://ionispharma.com/20240531" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Summit, a Broadridge Company
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html"/>
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_860bbe00be2841f2ac4879a63d0e55ac" contextRef="c20240531to20240531" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_ad0d516bb6db4a62a8be8c1695aa1e69" contextRef="c20240531to20240531">0000874015</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="ions-20240531.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="c20240531to20240531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-31</xbrli:startDate><xbrli:endDate>2024-05-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div><span style="font-size: 10pt;"> </span></div>

  <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/>
  <div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">Washington, D.C.&#160; 20549</div>

    <div style="font-size: 10pt;">&#160;</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_8c9505422dfc45f2a895c59e42a53f33" contextRef="c20240531to20240531">8-K</ix:nonNumeric></div>

    <div style="font-size: 10pt;">&#160;</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">PURSUANT TO SECTION 13 OR 15(d) OF THE</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SECURITIES EXCHANGE ACT OF 1934</div>

    <div style="font-size: 10pt;">&#160;</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Date of report (Date of earliest event reported):&#160; <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_8195bc82704c43d2987a4ad040b07325" contextRef="c20240531to20240531" format="ixt:date-monthname-day-year-en">May 31, 2024</ix:nonNumeric></div>

    <div style="font-size: 10pt;">&#160;</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_579871b3ae8c478f8f162976479dfd10" contextRef="c20240531to20240531">IONIS PHARMACEUTICALS, INC.</ix:nonNumeric><br/>
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(Exact Name of Registrant as Specified in Charter)</div>

    <div style="font-size: 10pt;">&#160;</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_74bbb893bbd14ca1a9669069d59fe31e" contextRef="c20240531to20240531" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br/>
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(State or Other Jurisdiction of Incorporation)</div>

    <div style="font-size: 10pt;">&#160;</div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_6d723c4bdf19416cb76c9421979a487e" contextRef="c20240531to20240531">000-19125</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 2%; vertical-align: top; font-size: 10pt;" colspan="1">&#160;</td>

    <td style="width: 49%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_6f4f0d9f380d49e8b719d6c683e1a0f5" contextRef="c20240531to20240531">33-0336973</ix:nonNumeric><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 49%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">(Commission File No.)</div>
          </td>

    <td style="width: 2%; vertical-align: top; font-size: 10pt;" colspan="1">&#160;</td>

    <td style="width: 49%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">(IRS Employer Identification No.)</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_85e2a3e100934c1f884397f60dff2067" contextRef="c20240531to20240531">2855 Gazelle Court</ix:nonNumeric><br/>
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_f663a130499848048d8404e212fec54c" contextRef="c20240531to20240531">Carlsbad</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_f46a0e4058f548e4b43a6634e1fc90ad" contextRef="c20240531to20240531">CA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_1db2912673874c239482edfe73ea15d3" contextRef="c20240531to20240531">92010</ix:nonNumeric></div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(Address of Principal Executive Offices and Zip Code)</div>

    <div style="font-size: 10pt;">&#160;</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Registrant&#8217;s telephone number, including area code: <span style="font-family: 'Times New Roman'; font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_f35cb1968a5444e0b26bf2dc8afcb68f" contextRef="c20240531to20240531">760</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_5bf69f0a450744c086ae3bcdb6e3dae9" contextRef="c20240531to20240531">931-9200</ix:nonNumeric></span></div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="font-size: 10pt;">
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>

    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
      </span></div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18.7pt; vertical-align: top; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_55db5e47111f47fda4ea64ed0fbcd0f0" contextRef="c20240531to20240531" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
          </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
          </td>

  </tr>


</table>
    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
      </span></div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18.7pt; vertical-align: top; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_22242677473f44b4ad5d4921d47de94e" contextRef="c20240531to20240531" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
          </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
          </td>

  </tr>


</table>
    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
      </span></div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18.7pt; vertical-align: top; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_7456d4732f2a44fa9ca0148041ac5777" contextRef="c20240531to20240531" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
          </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
          </td>

  </tr>


</table>
    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
      </span></div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18.7pt; vertical-align: top; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_a67e6062b62443039731955af2ed9c38" contextRef="c20240531to20240531" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
          </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;">&#160;</div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 31.1%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Title of each class</div>
          </td>

    <td style="width: 4.7%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 17.22%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Trading symbol</div>
          </td>

    <td style="width: 4.57%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 42.41%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Name of each exchange on which registered</div>
          </td>

  </tr>

  <tr>

    <td style="width: 31.1%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_5854b79c2cc04d6098b040db509fcdce" contextRef="c20240531to20240531">Common Stock, $.001 Par Value</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 4.7%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 17.22%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';">&#8220;<ix:nonNumeric name="dei:TradingSymbol" id="Fact_e15c9d785db94797af7d611d27dede9f" contextRef="c20240531to20240531">IONS</ix:nonNumeric>&#8221;</div>
          </td>

    <td style="width: 4.57%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 42.41%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_04aca79ab0cd44a58f80ef745d158eed" contextRef="c20240531to20240531" format="ixt-sec:exchnameen">The Nasdaq Stock Market, LLC</ix:nonNumeric><br/>
            </div>
          </td>

  </tr>


</table>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or
      Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).</div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td rowspan="1" style="width: 90%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: right; font-family: 'Times New Roman';">&#160; Emerging growth company</div>
          </td>

    <td style="width: 10%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman';"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_e9dc0f97ab154fb7999c05a9b6b93190" contextRef="c20240531to20240531" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </div>
          </td>

  </tr>


</table>
    <div> <br/>
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
      financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

    <div style="font-size: 10pt;">
<div>&#160;
      </div>
<hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/></div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 72pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 8.01</td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">Other Events.</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;">&#160;</div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">On May 31, 2024, Ionis Pharmaceuticals, Inc. issued a press release announcing positive results from the OASIS-HAE and OASISplus studies of donidalorsen in patients with
      hereditary angioedema (HAE).</div>

    <div style="font-size: 10pt;">&#160;</div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">A copy of this press release is attached as Exhibit 99.1 to this Current Report and incorporated herein by reference.</div>

    <div style="font-size: 10pt;">&#160;</div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 72pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 9.01.</td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">Financial Statements and Exhibits.</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;">&#160;</div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">(d) Exhibits.</div>

    <div style="font-size: 10pt;">&#160;</div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 16%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;"><span style="text-decoration: underline;">Exhibit No.</span></div>
          </td>

    <td style="width: 84%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-weight: bold;"><span style="text-decoration: underline;">Description</span></div>
          </td>

  </tr>

  <tr>

    <td style="width: 16%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';"><a href="ef20030319_ex99-1.htm">99.1</a></div>
          </td>

    <td style="width: 84%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Press Release dated May 31, 2024.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 16%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 84%; vertical-align: top; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 16%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">104</div>
          </td>

    <td style="width: 84%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Cover Page Interactive Data File (embedded within the Inline XBRL document).</div>
          </td>

  </tr>


</table>
    <div style="text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
      </span></div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-variant: small-caps; font-weight: bold;">SIGNATURE</div>

    <div style="font-size: 10pt;">&#160;</div>

    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf
      by the undersigned, thereunto duly authorized.</div>

    <div style="font-size: 10pt;">&#160;</div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 3%; vertical-align: top; font-size: 10pt;" rowspan="1" colspan="2">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-variant: small-caps; font-weight: bold;">Ionis Pharmaceuticals, Inc.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>

    <td style="width: 3%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>

    <td style="width: 47%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Dated:&#160; May 31, 2024</div>
          </td>

    <td style="width: 3%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman';">By:</div>
          </td>

    <td style="width: 47%; vertical-align: top; border-bottom: 2px solid black; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman';">/s/Patrick R. O&#8217;Neil</div>
          </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 3%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 47%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-variant: small-caps; font-weight: bold;">Patrick R. O&#8217;Neil</div>
          </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 3%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 47%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Executive Vice President, Chief Legal </div>
            <div style="text-align: justify; font-family: 'Times New Roman';">Officer and General Counsel</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="font-size: 10pt;">
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

  </div>

  <div><span style="font-size: 10pt;"> </span></div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ef20030319_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <!--PROfilePageNumberReset%Num%1%%%-->
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
  </div>
  <div style="text-align: left;"><br>
    <div style="text-align: left;"><img width="151" height="49" src="image0.jpg"></div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7197c4e3c5c546b480cb1ce66b568434">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Donidalorsen delivered significant and sustained reductions in HAE attacks, with high levels of disease control and improvement in quality of life measures with monthly or every
              two-month dosing; continued attack rate reduction over time</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2dd0b2187b9a4959ab571ac907270a8a">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">In first-of-its-kind prospective analysis, patients switching from prior prophylactic treatment to donidalorsen experienced further reductions in mean monthly HAE attack rates from
              baseline</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1f458ce77b8b4a88842f003202bc453c">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Donidalorsen demonstrated a favorable safety and tolerability profile across all cohorts</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2ae49fa89f7d44b9aa76caafda400ee5">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Data to be presented today at EAACI Congress 2024</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z36de24939de4448f85d6287cbd317fb5">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Ionis to host webcast on Friday, May 31 at 8:00am ET</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">CARLSBAD, Calif., May 31, 2024</font><font style="font-size: 10pt; font-family: 'Times New Roman';"> -- </font><u><font style="font-size: 10pt; font-family: 'Times New Roman';">Ionis Pharmaceuticals, Inc.</font></u><font style="font-size: 10pt; font-family: 'Times New Roman';"> (Nasdaq: IONS) today announced positive results from the
        Phase 3 OASIS-HAE and OASISplus studies of </font>donidalorsen<font style="font-size: 10pt; font-family: 'Times New Roman';"> in patients with hereditary angioedema (HAE) demonstrating significant and sustained </font>reduction in mean monthly
      HAE attack rates and continued attack rate improvement of &gt;90% with one year of treatment for both monthly or every two-month dosing. Patients who switched to donidalorsen from prior prophylactic treatment also <font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">showed 62% further reduction in mean monthly HAE attack rates from baseline, and 84% of patients who switched reported a preference for donidalorsen</font>. Donidalorsen <font style="font-size: 10pt; font-family: 'Times New Roman';">had </font>a favorable safety and tolerability profile across both studies, including when self-administered via an auto-injector. Results will be presented in three late-breaking oral presentations at the
      2024 European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress in Valencia, Spain<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">.</font> Based on these data, Ionis is pursuing regulatory approval
      of donidalorsen as a potential treatment for HAE.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">HAE is a </font>rare and potentially life-threatening genetic condition that involves recurrent attacks of
      severe swelling (angioedema) in various parts of the body, including the hands, feet, genitals, stomach, face and/or throat. <font style="font-size: 10pt; font-family: 'Times New Roman';">Donidalorsen is an investigational RNA-targeted prophylactic
        medicine designed to reduce the production of prekallikrein (PKK), interrupting the pathway that leads to HAE attacks.</font></div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;We&#8217;re delighted by the results from the OASIS clinical program, which we believe position donidalorsen to advance the prophylactic treatment paradigm for people living
      with HAE. Despite currently available therapies, people living with HAE still face significant disease burden and new prophylactic treatments are needed,&#8221; said Brett Monia, Ph.D., chief executive officer of Ionis. &#8220;These data underscore the potential
      of donidalorsen to continually improve HAE attack rates and quality of life over time, positioning donidalorsen as an attractive potential treatment option. In our prospective switch cohort, patients switched to donidalorsen from another prophylactic
      without increased breakthrough attacks and achieved greater disease control. In fact, a majority of patients who switched reported a preference for donidalorsen. We thank the patients, families and clinicians who participated in these important
      studies. Based on these results, Ionis will pursue regulatory approval for donidalorsen, and we look forward to launching it as part of our growing independent commercial pipeline, if approved.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">OASIS-HAE Study Results</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">In the Phase 3 OASIS-HAE study, patients with HAE were treated with donidalorsen (80 mg) <font style="font-size: 10pt; font-family: 'Times New Roman';">via subcutaneous
        injection </font>every four weeks (Q4W) (n=45) or every eight weeks (Q8W) (n=23), or placebo (n=22), over 24 weeks.</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd468723e744b4377a09f9c38f9be07b6">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">The study met its primary endpoint, demonstrating 81% lower monthly HAE attack rate with donidalorsen Q4W compared to placebo over weeks one to 25 (p&lt;0.001), and 55% reduction
              with Q8W (p=0.004).</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z507c7eb524224350a6a1a91e1ffc843f">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">In weeks five to 25, donidalorsen Q4W significantly reduced mean monthly HAE attack rates by 87% (p&lt;0.001) compared to placebo, a key secondary endpoint.</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: right;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">1</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div class="BRPFPageHeader" style="width: 100%;">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

            <tr>
              <td style="width: 50%; vertical-align: top;">
                <div style="text-align: left;"><img width="149" height="49" src="image00001.jpg"></div>
              </td>
              <td style="width: 50%; vertical-align: top;">&#160;</td>
            </tr>

        </table>
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z676e131ff0a24a2893929db52a7fd5c2">

        <tr>
          <td style="width: 54pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">o</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">In the same time frame, treatment with donidalorsen Q4W reduced severe to moderate attacks per month by 89% (p&lt;0.001).</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z982ef61a8289448682da9457d50e1963">

        <tr>
          <td style="width: 54pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">o</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Donidalorsen Q4W also reduced HAE attacks that require acute therapy by 92% (p&lt;0.001).</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze21afe3324564202b1323d65a4be67d1">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">At week 25, 91% of donidalorsen Q4W patients were well<font style="font-size: 10pt; font-family: 'Times New Roman';">-</font>controlled as measured by the Angioedema Control Test
              (AECT).</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z96faaa98ff564f19a3e7f592748753ea">

        <tr>
          <td style="width: 54pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">o</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Donidalorsen resulted in clinically significant improvement in quality of life as measured by the Angioedema Quality of Life Questionnaire (AE-QoL).</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0e343502383b4e2787c62ab417014edf">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Donidalorsen Q8W had a similar benefit as Q4W dosing over time on attack rate reduction and quality of life measures.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdcc1613bd506485a84765b3cb699e44e">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Donidalorsen was well-tolerated, with no serious treatment emergent adverse events (TEAEs) related to donidalorsen. Most adverse events (AEs) were mild or moderate in severity, and
              injection site reactions were the most common AE. One patient in the donidalorsen Q8W group discontinued based on investigator recommendation due to patient noncompliance and a TEAE.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">OASISplus Study Results &#8211; Open-Label Extension and Switch</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The OASISplus study included an open-label extension (OLE) cohort and a first-of-its-kind prospective cohort to assess patients switching from both newer
      oral and injectable long-term prophylactic treatments to donidalorsen.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Open-Label Extension Cohort</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Following completion of the placebo-controlled treatment period in OASIS-HAE, 94% of eligible patients
        enrolled in the OLE cohort. </font>Participants continued to receive treatment with donidalorsen via subcutaneous injection dosed every four weeks (n=69) or every eight weeks (n=14). As of the February 28, 2024 data cut:</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z844cf65fb4b94794b36e6256f5f3addf">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Attack rates continued to improve over time, resulting in 93% and 92% improvement from baseline measured at the start of OASIS-HAE across Q4W and Q8W, respectively.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb95d2678cfdb45e19d2e7ddf2382412d">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Extended treatment resulted in further improved quality of life measures and high levels of disease control.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z94a54dbb317b4286a7a7991df04ccc1f">

        <tr>
          <td style="width: 54pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">o</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">At week 25, 91% (Q4W) and 100% (Q8W) </font>of patients reported well-controlled disease as measured by the AECT.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z220623c1466049bf88d01d2d22841575">

        <tr>
          <td style="width: 54pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">o</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">AE-QoL scores improved by 28 points (Q4W) and 24 points (Q8W) at week 25 compared to baseline in OASIS-HAE. An improvement of 6 points is considered clinically meaningful.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7a34a06bf45a4fef900f993332fe85c7">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Safety results were consistent with findings from OASIS-HAE, with no serious safety concerns and no patient discontinuations.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Switch Cohort</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The OASISplus switch cohort evaluated the safety and efficacy of long-term dosing of donidalorsen every four weeks in patients (n=64) who were previously treated with
      another prophylactic HAE medication (lanadelumab, berotralstat or C1-esterase inhibitor) for at least 12 weeks prior to entering the study. Patients followed a pre-defined specific protocol to transition from their prior therapy to donidalorsen.
      Results from a pre-defined endpoint of 17 weeks indicate:</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z872132affd374d1fb0c37095db84b574">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Patients switched to donidalorsen from prior prophylactic treatment without an increase in breakthrough attacks.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfd8a349d80254aacbcf19620adbd4da1">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Patients experienced a 62% further improvement in mean monthly HAE attack rate compared to baseline for previous prophylactic treatment.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z56e73b6a47374ae1946b5b58a6b540fe">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">84% of patients who switched reported a preference for donidalorsen over their previous treatment, citing better disease control, less time to administer, and less injection site
              pain or reactions.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup></div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze48754b9a1f145cba3244d09d4e50053">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Quality of life measures also showed continued improvement, with 93% of patients reporting well-controlled disease compared to 67% at baseline with prior prophylactic treatment.
              Results also demonstrated &#8805;8-point improvement in AE-QoL scores.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc10dfb6914ba4e55bde62ff0e4677480">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Safety results were consistent with findings from OASIS-HAE, with no serious safety concerns. One patient discontinued due to TEAE not related to donidalorsen.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: right;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">2</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div class="BRPFPageHeader" style="width: 100%;">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

            <tr>
              <td style="width: 50%; vertical-align: top;">
                <div style="text-align: left;"><img width="149" height="49" src="image00001.jpg"></div>
              </td>
              <td style="width: 50%; vertical-align: top;">&#160;</td>
            </tr>

        </table>
      </div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;People living with HAE are facing a lifelong battle, and I see that impact firsthand in my practice. It&#8217;s critical for treatment options to have lasting, durable
      efficacy,&#8221; said Marc Riedl, M.D., M.S. clinical director, U.S. HAEA Angioedema Center; clinical service chief, Division of Allergy &amp; Immunology, University of California, San Diego. &#8220;The OASISplus study demonstrated patients are able to change
      therapy to donidalorsen without the risk of increased breakthrough HAE attacks while continuing to improve in measures of quality of life and disease control.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;The comprehensive OASIS clinical program demonstrates how donidalorsen can potentially address key concerns patients may experience with currently available treatment
      options,&#8221; said Kenneth Newman, M.D.<font style="font-size: 10pt; font-family: 'Times New Roman';">,</font> senior vice president of clinical development at Ionis. &#8220;Donidalorsen significantly reduced HAE attack rates, and with the simplicity of
      monthly or every two-month self-administration via autoinjector, we believe that donidalorsen has a unique profile that may address the needs of people with HAE.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Ionis plans to file a New Drug Application this year with the U.S. Food and Drug Administration (FDA), marking progress toward the goal of launching our second wholly owned
      medicine. Otsuka Pharmaceutical Co., Ltd., which has exclusive rights to commercialize donidalorsen in Europe, is also preparing to submit a Marketing Authorization Application to the European Medicines Agency this year.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">All presentations can be found on Ionis' <u><font style="font-size: 10pt; font-family: 'Times New Roman';">website</font></u> after today's presentations at 10:45am ET.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Webcast</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Ionis will hold a webcast today at 8:00am ET to discuss this update. Interested parties may access the webcast <u><font style="font-size: 10pt; font-family: 'Times New Roman';">here</font></u>. A webcast replay will be available for a limited time.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About the OASIS-HAE Study</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The global, multicenter, randomized, double-blind, placebo-controlled Phase 3 OASIS-HAE study (<u><font style="font-size: 10pt; font-family: 'Times New Roman';">NCT05139810</font></u>)
      enrolled 91 participants, age 12 and above, with HAE-1 and HAE-2 hereditary angioedema. Participants were randomized in a 2:1 ratio to receive donidalorsen (80mg) or placebo via subcutaneous injection once every four weeks for 24 weeks or
      donidalorsen (80mg) or placebo via subcutaneous injection once every eight weeks for 24 weeks. Within each cohort, participants were randomized in a 3:1 ratio to receive donidalorsen or matching-placebo. The primary endpoint was the time-normalized
      number of investigator-confirmed HAE attacks from week one to week 25 compared to placebo. Following completion of the treatment period, 94% of eligible patients entered the Phase 3 OASISplus open-label extension study.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About the OASISplus Study</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The Phase 3 OASISplus open-label extension (OLE) study is a 53-week global, multicenter study of subcutaneous injections of donidalorsen administered every four weeks
      (80mg) and every eight weeks (80mg) in patients completing the OASIS-HAE study. These are patients aged 12 and above, with HAE-1 and HAE-2 hereditary angioedema. The study is designed to evaluate the safety and efficacy of extended dosing of
      donidalorsen following completion of the Phase 3 OASIS-HAE study. The OASISplus switch cohort is evaluating the safety and efficacy of long-term dosing of donidalorsen every four weeks in patients who were previously treated with another prophylactic
      HAE medication. Additional information about OASISplus (<u><font style="font-size: 10pt; font-family: 'Times New Roman';">NCT04307381</font></u>) may be found at <u><font style="font-size: 10pt; font-family: 'Times New Roman';">ClinicalTrials.gov.</font></u></div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About Hereditary Angioedema (HAE)</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">HAE is a rare and potentially life-threatening genetic condition that involves recurrent attacks of severe swelling (angioedema) in various parts of the body, including the
      hands, feet, genitals, stomach, face and/or throat.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2,3,4,5,6</sup> HAE is estimated to affect more than 20,000 patients in the U.S. and Europe.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">7</sup> In the U.S., doctors frequently use prophylactic treatment approaches to prevent and
      reduce the severity of HAE attacks in patients.</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: right;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">3</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div class="BRPFPageHeader" style="width: 100%;">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

            <tr>
              <td style="width: 50%; vertical-align: top;">
                <div style="text-align: left;"><img width="149" height="49" src="image00001.jpg"></div>
              </td>
              <td style="width: 50%; vertical-align: top;">&#160;</td>
            </tr>

        </table>
      </div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About Donidalorsen</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Donidalorsen is an investigational <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">LI</font>gand-<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">C</font>onjugated <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">A</font>ntisense (LICA) medicine designed to target prekallikrein (PKK), which plays an
      important role in activating inflammatory mediators associated with acute attacks of hereditary angioedema (HAE). By reducing the production of PKK, donidalorsen could be an effective prophylactic approach to preventing HAE attacks.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About Ionis Pharmaceuticals, Inc.</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading
      pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of
      disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">To learn more about Ionis, <font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">visit </font><u><font style="font-size: 10pt; font-family: 'Times New Roman';">Ionispharma.com</font></u><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> and follow us on </font><u><font style="font-size: 10pt; font-family: 'Times New Roman';">X</font></u><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> (Twitter) and </font><u><font style="font-size: 10pt; font-family: 'Times New Roman';">LinkedIn</font></u><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">.</font></div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Ionis Forward-looking Statements</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">This press release includes forward-looking statements regarding Ionis' business, financial guidance and the therapeutic and commercial potential of our commercial
      medicines, donidalorsen, additional medicines in development and technologies. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an
      at-risk statement. Such statements are subject to certain risks and uncertainties including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the
      endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such
      forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no
      obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual
      report on Form 10-K for the year ended December 31, 2023, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our" and "us" all refer to Ionis Pharmaceuticals and its subsidiaries.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Ionis Pharmaceuticals<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> is a registered trademark of Ionis Pharmaceuticals, Inc.</div>
    <div><br>
    </div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Ionis Investor Contact:</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">D. Wade Walke, Ph.D.</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><u><font style="font-size: 10pt; font-family: 'Times New Roman';">info@ionisph.com</font></u> 760-603-2331</div>
    <div><br>
    </div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Ionis Media Contact:</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Hayley Soffer</div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><u><font style="font-size: 10pt; font-family: 'Times New Roman';">CorporateCommunications@ionisph.com</font></u> 760-603-4679</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z11c95009746f413b8122b534c8d7176a">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">1.</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Patients selected a reason for switching from a predefined list of reasons.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z35b16ffdca8e486cabc2333a3e9a8680">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">2.</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Manning ME. Dermatol Ther (Heidelb). 2021; 11:1829-1838.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z98fb3eb663d447c08e91d6dc54e15489">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">3.</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Valerieva A, et al. Balkan Med J. 2021;8:89-103.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z12e57ea8a5724d6b82771a9e968ea682">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">4.</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Santacroce R, et al. J Clin Med. 2021;10:2023.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfbf4b2a080954e80bd794b5812b1bf08">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">5.</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Pines JM, et al. J Emerg Med. 2021;60:35-43.X</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z337257157604431c8ce267b00fce2eb8">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">6.</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Maurer M, et al. World Allergy Organ J. 2022;15:100627.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z81f2100fb07043bd86b9149a7aba8df1">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">7.</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Weller K, et al. Allergy. 2016;71(8): 1203-1209.</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div> <br>
    </div>
    <div style="text-align: right;"> <font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">4</font> </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ions-20240531.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 24.3.1.5224 Broadridge-->
<xs:schema targetNamespace="http://ionispharma.com/20240531" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:ions="http://ionispharma.com/20240531" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="ions-20240531_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ions-20240531_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://ionispharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ions-20240531_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 24.3.1.5224 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract" xml:lang="en-US" id="dei_CoverAbstract">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract" xlink:title="label: CoverAbstract to dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType" xml:lang="en-US" id="dei_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType" xlink:title="label: DocumentType to dei_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications" xml:lang="en-US" id="dei_WrittenCommunications">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications" xlink:title="label: WrittenCommunications to dei_WrittenCommunications" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial" xml:lang="en-US" id="dei_SolicitingMaterial">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer" xml:lang="en-US" id="dei_PreCommencementTenderOffer">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag" xml:lang="en-US" id="dei_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag" xlink:title="label: AmendmentFlag to dei_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus" xml:lang="en-US" id="dei_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate" xml:lang="en-US" id="dei_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName" xml:lang="en-US" id="dei_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey" xml:lang="en-US" id="dei_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber" xml:lang="en-US" id="dei_EntityFileNumber">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber" xlink:title="label: EntityFileNumber to dei_EntityFileNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1" xml:lang="en-US" id="dei_EntityAddressAddressLine1">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2" xml:lang="en-US" id="dei_EntityAddressAddressLine2">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3" xml:lang="en-US" id="dei_EntityAddressAddressLine3">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown" xml:lang="en-US" id="dei_EntityAddressCityOrTown">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince" xml:lang="en-US" id="dei_EntityAddressStateOrProvince">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry" xml:lang="en-US" id="dei_EntityAddressCountry">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode" xml:lang="en-US" id="dei_EntityAddressPostalZipCode">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode" xml:lang="en-US" id="dei_CityAreaCode">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode" xlink:title="label: CityAreaCode to dei_CityAreaCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber" xml:lang="en-US" id="dei_LocalPhoneNumber">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle" xml:lang="en-US" id="dei_Security12bTitle">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle" xlink:title="label: Security12bTitle to dei_Security12bTitle" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag" xml:lang="en-US" id="dei_NoTradingSymbolFlag">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol" xml:lang="en-US" id="dei_TradingSymbol">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol" xlink:title="label: TradingSymbol to dei_TradingSymbol" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName" xml:lang="en-US" id="dei_SecurityExchangeName">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ions-20240531_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 24.3.1.5224 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://ionispharma.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="ions-20240531.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://ionispharma.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !Q 5H# 2(  A$! Q$!_\0
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M6+IY=C,35P]"K5Y:$<35A&A]8J4*#J*K7HQJ?IM1117S9^)!1G'6BOA7]O\
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MA.GBZ3Q]2C+ X3!NHL)C9PQ.(Q-.M#+_ &%;QB/]C+Q=X;N[7PS\./BC\/\
M0/A"D_@)XM-\8? F#X@?&GPI9?"V_DO?AAI?P_\ B]<_$;1/#5G#\+4:VM?A
MIJ7Q(^$'Q4U_P]%I]O\ VWJWBSS+@/Z1;?L+_LJ_9X/[;^#7A3QCK/DQ?VOX
MN\:02^)?&/BG4]B_;_$?BSQ'J+RZAK_B77+KS=3UW6[^22]U75+JZOKIWGG=
MC];45^-2S''2_P"8FI!]94N6C.;22O5G24)57:*2E4<FELT?YG5N-.*:UO\
MA9Q>&GHZE7+_ &668C$R4(TU4QN(RZGA:^/JJ$(157&U*]1*.DM[_P"//111
M7]9G_1 ?T/?\&RG_ "D6\1_]FS_$O_U,?AA7]_5?P"_\&RG_ "D6\1_]FS_$
MO_U,?AA7]_5?S[XD_P#)2R_[ <)_[D/\=?IO?\GOJ_\ 9)\/_P#I6//YMO\
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M.E*YBBN==U;2K*2YMENC/'_J:JBH J@  8    'H  ,#H,#C@5_-Q_P;L_\
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M?_R(,9_V.,1_ZA9>?UW] O\ Y-!Q)_V<G./_ %E^#@K^\_\ X-<O^3 /B_\
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M:G0Q.'J*-;#8FG5P]>$*U*<(E%%%=)[9_?3_ ,&PW_*/+QYQ_P W5?$;\?\
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MO^P[>_\ I%IE>VT45X^)_CU/5?\ I*/S#.?^1ICO^O\ +\D?-_[0?^I\+_\
M7;5__1>FU\ST45Z6&_@4_1_^E,^[X=_Y$V$_Q8G_ -2*@5]P_";_ ))_X=_Z
MY:A_Z=;RBBLL;_"C_P!?%_Z3,X>+/^1?0_[#(?\ IFN>CT445Y9^?A5:Y_U4
MW_7*;_T51136Z]5^8UNO5?F?Q!?\%I_^/CQ'_P!@^^_])Y*_EMHHK^F.$?\
MD2X;T7_I$#_<GZ-O_)L<I_PP_P#343^B_P#X(E_\C5X>_P"OV\_]*I:_O;T[
M_CQL?^O.V_\ 1$-%%?DGB'_R.E_U[?\ [:?YX_3*_P"3G2_Z]U__ $ZB]111
+7P)_(84444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #$ E@# 2(  A$! Q$!_\0
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M#V'P^08-X*C1C&E3PD\/EM.>&A3C&*HR@DD%%%%>(?E(4444 %%%% !1110
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MN]6_5]6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\2VEO%)<WMZ_S7.G^"_#'VK3[KQ;KT-O<&QBOM-TVVAFU?6]*M;G_.&_:?\
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M?"O2C8:U\3?$OV3Q5\:_'MM %E\6>.;BU"RV5C</''=?\(CX0@>30?"-G,(
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MHR<HRBZ=>A4K8:M0K5"BBBN\^P"O](+_ ((=_MS7/[:G[%^@6_C76'U3XU?
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MHOB#P_JECK6BZQI]PI:WOM+U;39[FQU"SG0[H+JUGF@D4@HY'(_G[Q&AF?\
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M(T&6#X$>'=5M@;GP)\-M:MPMWX[G@N(R]EXI^(5DWV?1I(MEUI?@&:4>>_\
MPFFI6-A_4O5>&&&VABM[>**"""*.&""&-888885$<4444858XXT551%4*B@(
M@Q@"Q7Y3G.;XK.\QKYABG[]65J=--N%"A%OV5"GVC!/5V7/-SJ-<TY,_SV\3
M?$3/?%+C+-N,<^J6Q&/J>SP6"A.4\-E.5T')8'*\(I6M1PM.3<Y*,'B,34Q&
M+J1]MB*C91117E'P(4444 ?X\]%%%?V ?]) 4444 ?TD_P#!KE_R?_\ %_\
M[,\\?_\ JZOV?:_O/K^##_@UR_Y/_P#B_P#]F>>/_P#U=7[/M?WGU_/?B/\
M\E-5_P"P/"?^D2/\;/IK?\GRQ_\ V37#G_J-5"OYE_\ @Z!^-\_@K]D/X/?
M_3[Z2UO?CC\7I-8U>W68I_:?@SX2:.NJZG92P*ZF:&/QCXJ^'NI999(H9M/@
M+1B5X73^FBOX9?\ @Z6\?S:M^UK^SY\,UN%FL?!'[/K^+S$CK(+35OB)\0?%
M.F7T4RB=O)N7TWX>:)<-%);0.;::SFWS1S0^3Q<"82.+XGRY32<,.ZV+E?\
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MTPN?#.HVL ;[)\/-<U&59O NM)'%I^CW%\G@.^2SN+/PU>>*/YYZ_P!?[7]
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M*G7P^(P]6%>A7HU8J5.K1K4W*G5ISB^:$X2E&46I)M,****HW"BBB@ HHHH
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MZKX4?\S_ /[I?_O1/]!/V>W_ #=W_NP?_?U"BBBOV _TD"OZ2?\ @UR_Y/\
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MSD\92=#,,@K4:>.]DO@6*R/&UJ6.IXB4=94L \SH0=E]:DVD?U)T5^)NA?\
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M_O1/])/V>W_-W?\ NP?_ ']0HHHK]@/]) K^DG_@UR_Y/_\ B_\ ]F>>/_\
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MIVD6T$.FZ7IGPPG2&^F^&VH:'HEM::=9ZGIMG?V^M26L>I^-M*\5ZC)+>/\
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M[JC@<?-8MJE1Q688A?P9T445^['^LX4444 %?MO_ ,&\O_*4[X)_]B=\:/\
MU57BJOQ(K]M_^#>7_E*=\$_^Q.^-'_JJO%5>)Q+_ ,D]G?\ V*L?_P"HU0_*
M_''_ ),WXI?]F_XL_P#5+BS_ $8:***_EH_P+"OXPO\ @ZU_Y*!^Q;_V)WQL
M_P#3W\-J_L]K^,+_ (.M?^2@?L6_]B=\;/\ T]_#:OL_#_\ Y*O+O\&._P#4
M'$G]-?0^_P"4@>"O^P?BC_UE,Z/Y)****_HT_P!K@HHHH _U5?\ @GC_ ,F
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MVO>!K&T77=4U*WT34K%-833)-/@_SU9(Y()'AFC>*6)VCEBD5TDCD1RKHZ,
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M_P"#7+_D_P#^+_\ V9YX_P#_ %=7[/M?WGU_!A_P:Y?\G_\ Q?\ ^S//'_\
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MGK]@\*/^9_\ ]TO_ -Z)_I)^SV_YN[_W8/\ [^H4445^P'^D@5_23_P:Y?\
M)_\ \7_^S//'_P#ZNK]GVOYMJ_I)_P"#7+_D_P#^+_\ V9YX_P#_ %=7[/M?
M-\7_ /),YS_V!R_]+@?B'TD?^3&^)?\ V35?_P!2<*?WGT445_,9_A,%%%%
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MFI8C!8O$5_R0HHHK]./[P"OVW_X-Y?\ E*=\$_\ L3OC1_ZJKQ57XD5^V_\
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MG'\/8J>B=6O@J?UC-<JE)M?NZ<<UP^DJD\3AH-4X_P *M%?JG^TK_P $7?\
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M"]UK7-1G>+3M"\/Z8DL<FJ:YJ]U::78Q,GVFY1WB23_1;_X)6_\ !+SX<_\
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M[_@F9_T*_P 8O_#M:K_\KZ**/[9SC_H:YE_X78K_ .6A_P 1,\1_^C@<;_\
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M]LYQ_P!#7,O_  NQ7_RT_K+_ (B9XC_]' XW_P#$KS[_ .;_ "7W!_Q#??\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140157459615440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 31,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-19125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">IONIS PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000874015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0336973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2855 Gazelle Court<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Carlsbad<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">931-9200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $.001 Par Value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IONS<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MIR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%
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M>FR-9V87YTC'?8Q']>5=2(6NF9MYEJ6R!F_236P@R*2*Y U+2X<L-03&IAJ
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M4')O<',O8V]R92YX;6Q02P$"% ,4    " #N.;]8F5R<(Q &  "<)P  $P
M            @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M .XYOUAI#,:@4@0  (\0   8              " @0T(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    " #N.;]8GZ ;\+$"  #B#   #0
M            @ &5#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( .XYOUB7
MBKL<P    !,"   +              "  7$/  !?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( .\YOU@<.&7J/P$  #P"   /              "  5H0  !X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    " #O.;]8)!Z;HJT   #X 0  &@
M        @ '&$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    " #O.;]899!YDAD!  #/ P  $P              @ &K$@  6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #U$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ef20030319_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionispharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ef20030319_8k.htm">ef20030319_8k.htm</File>
    <File>ions-20240531.xsd</File>
    <File>ions-20240531_lab.xml</File>
    <File>ions-20240531_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ef20030319_8k.htm": {
   "nsprefix": "ions",
   "nsuri": "http://ionispharma.com/20240531",
   "dts": {
    "inline": {
     "local": [
      "ef20030319_8k.htm"
     ]
    },
    "schema": {
     "local": [
      "ions-20240531.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ions-20240531_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ions-20240531_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 29,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://ionispharma.com/role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20240531to20240531",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030319_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240531to20240531",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030319_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001140361-24-028247-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-24-028247-xbrl.zip
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M,W!1N%QADB3 IMMJ%*7+R&2)DLW&/-U,3"ANB6)11U=4HSKF+-G* 6X+2DO
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M]>]S3Q9<T9",4X IGVJ$LHU.$9W/@W3AA&9)9Q&THV)LK,2VZ!R[T/<M3[*
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M\^G*DEX@EO<1A"MB0?,&W23Q7384@8LX=BEV)S/N!U&^-SE?9E#-T@-?66.
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MD)-$; _+AO.J.=Y2:Q=?YL>!BPW'>3KY0__J[(K<\ \))]_$WK'%%J=*#V.
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M)5<)AE0DD/C':$5UMR)LT8C,'+Y4]]!16R,C1H])5B 7!;5PWH(NH M TN4
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MB5)W8XX;RXA&9( \10+ UOOW0:=2Z>L(>< PI#]!]5\I9$H60,'-Z/U?O@-
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MXHYY5$H/F>HIR"8'M* 8+F0I_G1@2;*9.$+\<+]0@3DG^ES)2.TJ!%'&4GD
MZG>:%.Q4>D*6RU665#?1N5)YHZ:>DD;CP)HQJ@MT.L<Z^F#]K&Y&<OM^>317
MBE@D5B84E I4[4KN@=E;DB914K#OI)_830--PE3!1R^HIP<)'%#5QW/A%/2J
M@Q00S[9M2#3N%T]#74A;)F4PFSI!I45I/2!Y33%?!YA-O3Q[\YM3>G5_CZF"
M2[NPGJA)Z(!J>WP79(W>=>@:.LV8;1CM&%%E1:5YOS!;5)+8YER&6Z\7D+\
M#O^PG^?Y"E-KY+5R&'Q WAW^VK%TN B@&)9+H=FUN2 J37_7A;[<\.IHPP->
M(XU>FI723I.']7+,(L<\^ED:+A0H05L]5<7F@#T8Q85QU:$.:%DWVQPB?KQ?
M3N',$T/"9 (EB<#-7#*/&P)G21Z%Z9\XI&>L1?T&UZ)2M@D:J@YV##21N]@\
M:+INVT=0>VRW%"H+XB94VOJQOZ"K&[%*,KSKH(C5#8@V"+RS7.U@M],,Z$">
M)5UG1 /1NV-:=FY']6Z?!M>5L7]D0S4$V=87&Z1[1P[S;8+"(^&;'Y=^9=]1
M-72#&H5L1=,!U6#4+HA6';?1+.NW)-<(,P/BEGY0#->*6*06IE>2JN2:B^Z!
MVM.,C?+Y!B\2_D-'5ER&2Q4ADZ2>(BQQ0-84TX58C5\=L*!\5K6B;3/B[?NE
MU5@DTIY4F55(*5"UJK4W4D_8(J%A>LZ^Y*U_P\\@JAJ-Q&I#XPRK)JH[K4W'
M9EQ5O>"U;D>E 3%+'XC5U8I8I!9B5I'*T+85W1NU9TF*+U?+>6/_3&>66-TU
M.V/:C.5.J.33#.>.5'#)FU#5U@<B@6(0<P(A#K<J&4%#+;W1=Q>NSV.&?G)?
M_Y)G0+%%*W&IU3I#VC(*=V+U <SXZOH)EID=R8(>D=U66_*"$D#,:[K("\ 6
M&F^KX3R+"'TDM Q^6[#[[!.R8M>%YQ,2P[>^5CVDE='2PWE]6(W(?96TA3&O
M%7-OL6(DU1M4ZA"AJ-8B+N[#XK&#@+RX2M!",G:4E]/+2/.VJ$Z7F"Z2;/&1
MDJ?BX80L'\,,OCDW*J5%I%$Z+Q[C"-P7C<Z]>;' O<0B$594F5%M[\.Z,->3
M6"<>6@=@!YE_.TB\<7\<QXRWO/YSD61X E)OT$G,@SIGX@W1W7F'G9MIA_H(
MUNO&-^(#XF9TE?7B*F"J([%,.40Z()<YMP'C%2D/+"D/+"D/O% >^*0\^ K*
M@Q;*[YY(/RD/;"E7"]Y">=!&>1.,5Z1\:DGYU)+RJ1?*ISXIGWX%Y=,VREF1
M>GHVG]IRKI:\A?-I&^=--'QS?L(^7M$[\I29*&^J(,9W55T1WHS<&=^2:RNZ
M=WHTV.8V_HV56WM$-5 YB&EM@2&BMV*09P,&OFDNO_I>T6M*OB19 RX;*<1U
M0]H5W)HQ=$9XT[\5YFJW!NN;[1DAZ1'PNKI"U)L9@-!7>H#\M^'B_91>;?T8
MS^>R!#R9"TEG9W(Y9G>G\8U?NW-X+6^>P"M#CU!6JP2>N,%*@F?M>BL5/&5K
MBNT;U6N2%V'Z5_*HW74W"2%L%6%7\(+Q.T-8]6X%LMRI@7-E1LS>F\US8RTA
MN$U5AQ"7]"#H9CQ\O"R QZ8X! "'3/7D9)/+FP* &$XO"I#]:=\3L"N;E;?&
M_+ ')()))_IDR;3M*C9O"##5R@-1_$5(Z?4#R>#_2Z(SUQ-IFAWHTL5R(0SP
MJ:.L(9V5+:ALZL4O[MIB$',"9>I4E2"OM98^GLS&T8HRXB?!_(X/4J%"9ZXG
MU#2[/).MB>7T1';3I_9Y;%4Z*_\@<H\FP0_S'Y$0[/F);%U%B#F+,H*J:O,L
M=EM!/2!X2>YHR-]7=_N\G),4>.3.H*BG!2H<6#1$=,$1=JLC$E+/+@FJ6U'5
MW(,'\TSU(:T)E<D$A ).FR)[X%,*JK "VNH)*38'&L$H+ARJ#G4$RKJ9#-Y^
MF8,S3PP)DSF3)((P<\D\7GY/U]$#*P &'M0P293+L"SIX%(,Q>SB<JSX;;LD
M2_*9:$6BN0</:AB+1-J3"E^==Y7J%1JJ]6X.+M@G_M;6NBFIWG(Z^Q]02P,$
M%     @ [SF_6$8/*Z[?!0  ]SX  !4   !I;VYS+3(P,C0P-3,Q7W!R92YX
M;6S56UUOXC@4?5]I_T.6>8:4T)E=JC(CMM..JF%:5%CMQ\O*) :L36+DA +_
M?NU@4^+83IBVH]N7%G*/K\_U.7'()5Q^VB:Q]XA91F@Z:'4[9RT/IR&-2+H8
MM-99&V4A(:U/'W_^Z?*7=OL+3C%#.8Z\V<[[G5$4,1(ML#=^N)^3&'O!>:?7
MZ7;>!\'Y4;C=%L-CDOYW(?[,4(8]/FV:76PS,F@M\WQUX?N;S::SZ74H6_C!
MV5G7_^O;:!(N<8+:),URE(:XY7'\158<'-$0Y07GH^';&8M5@IY_F,N*$._:
M"M86A]K=H-WK=K99U)(41;C!) J^K>!E3=U^O^\7T0.4)R*.U(>R^>IYWG[]
M&(WQ YY[XO\?#[?6T7U?(/P4YR,TPS&?LAB>[U9XT,I(LHJQ.K9D>&[.$S-V
M2"-6IR]6I_M!K,Z[I\S^<^@MA)FF-$?QR_ L\E6Y5J9Y/NF[EUI:%^6[EUQE
M?I+C'[#*1],\G_08,T*CZS1Z?>+Z5"]%?I(C]@.L4IWL^06\/NL3J/+-GF2K
M)6()ZH0TV6?_3,-U@M-\F'+E<I+O;M,YY0AQ::@GSD$9)Q:<G[W?;_KOW/F.
M::X8SCBPB(SX@=)D>)OC-,*1FDYP?48AQ;1JXIB&I;EB<26DK"I)QN<J],AP
MV%G01S_"A&L<],0+47:O*)F_^?>*\H\ PUF6,Q3F*E,LM!FTC#'.4%2DQ?Q7
M)ZJ6:<HS:CQ-(4FS'"JS/-9QR,J,$0M5)OZR)&+U<BT1_@HQGJ\=+DE\T'_.
M:&);2>JD?DSOPBME\'+JE4=2%F$V:)V)3W%\X!PS)D\Q!^^"='Q\'KZF@$/.
M-A*,;V*TT!0TQN0Z:#%X&KK(UXBH#94J=@&KJ&QWN&9^YINYY7PT8K034\/
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M,#,Q.5]E>#DY+3$N:'1M4$L! A0#%     @ [SF_6%S'=6%% P  0@\  !$
M             ( !!S$  &EO;G,M,C R-# U,S$N>'-D4$L! A0#%     @
M[SF_6 ?PY8IZ"   ,%8  !4              ( !>S0  &EO;G,M,C R-# U
M,S%?;&%B+GAM;%!+ 0(4 Q0    ( .\YOUA&#RNNWP4  /<^   5
M      "  2@]  !I;VYS+3(P,C0P-3,Q7W!R92YX;6Q02P4&      4 !0!'
) 0  .D,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>ef20030319_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ions-20240531.xsd" xlink:type="simple"/>
    <context id="c20240531to20240531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <startDate>2024-05-31</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20240531to20240531"
      id="Fact_860bbe00be2841f2ac4879a63d0e55ac">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20240531to20240531"
      id="Fact_ad0d516bb6db4a62a8be8c1695aa1e69">0000874015</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="c20240531to20240531"
      id="Fact_8c9505422dfc45f2a895c59e42a53f33">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20240531to20240531"
      id="Fact_8195bc82704c43d2987a4ad040b07325">2024-05-31</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20240531to20240531"
      id="Fact_579871b3ae8c478f8f162976479dfd10">IONIS PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20240531to20240531"
      id="Fact_74bbb893bbd14ca1a9669069d59fe31e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20240531to20240531"
      id="Fact_6d723c4bdf19416cb76c9421979a487e">000-19125</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20240531to20240531"
      id="Fact_6f4f0d9f380d49e8b719d6c683e1a0f5">33-0336973</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20240531to20240531"
      id="Fact_85e2a3e100934c1f884397f60dff2067">2855 Gazelle Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20240531to20240531"
      id="Fact_f663a130499848048d8404e212fec54c">Carlsbad</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20240531to20240531"
      id="Fact_f46a0e4058f548e4b43a6634e1fc90ad">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20240531to20240531"
      id="Fact_1db2912673874c239482edfe73ea15d3">92010</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20240531to20240531"
      id="Fact_f35cb1968a5444e0b26bf2dc8afcb68f">760</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20240531to20240531"
      id="Fact_5bf69f0a450744c086ae3bcdb6e3dae9">931-9200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20240531to20240531"
      id="Fact_55db5e47111f47fda4ea64ed0fbcd0f0">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20240531to20240531"
      id="Fact_22242677473f44b4ad5d4921d47de94e">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20240531to20240531"
      id="Fact_7456d4732f2a44fa9ca0148041ac5777">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20240531to20240531"
      id="Fact_a67e6062b62443039731955af2ed9c38">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20240531to20240531"
      id="Fact_5854b79c2cc04d6098b040db509fcdce">Common Stock, $.001 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20240531to20240531"
      id="Fact_e15c9d785db94797af7d611d27dede9f">IONS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20240531to20240531"
      id="Fact_04aca79ab0cd44a58f80ef745d158eed">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20240531to20240531"
      id="Fact_e9dc0f97ab154fb7999c05a9b6b93190">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
